🟢 Amneal Pharmaceuticals is trading 4.03% up with no clear catalyst identified

Amneal Pharmaceuticals is trading at $20.57, up 4.03% on September 28, with no verified catalyst identified for the intraday gain.

• News coverage cited the lanreotide FDA approval and launch, but the approval had already been announced on September 18.
• Broader markets were weaker amid rising oil and rate concerns; available evidence does not show Amneal moving with the market.